Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC)
Copyright © 2024 Elsevier B.V. All rights reserved..
Lung cancer is the one of the most prevalent cancer in the world. It kills more people from cancer than any other cause and is especially common in underdeveloped nations. With 1.2 million instances, it is also the most prevalent cancer in men worldwide, making about 16.7% of the total cancer burden. Surgery is the main form of curative treatment for early-stage lung cancer. However, the majority of patients had incurable advanced non-small cell lung cancer (NSCLC) recurrence after curative purpose surgery, which is indicative of the aggressiveness of the illness and the dismal outlook. The gold standard of treatment for NSCLC patients includes drug targeting of specific mutated genes drive in development of lung cancer. Furthermore, patients with advanced NSCLC and those with early-stage illness needing adjuvant therapy should use cisplatin as it is the more active platinum drug. So, this review encompasses the non-small cell lung cancer microenvironment, treatment approaches, and use of cisplatin as a first-line regimen for NSCLC, its mechanism of action, cisplatin resistance in NSCLC and also the prevention strategies to revert the drug resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:828 |
|---|---|
| Enthalten in: |
Mutation research - 828(2024) vom: 19. März, Seite 111856 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Umar, Hassaan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cisplatin |
|---|
| Anmerkungen: |
Date Revised 23.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.mrfmmm.2024.111856 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370104463 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370104463 | ||
| 003 | DE-627 | ||
| 005 | 20240324235428.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mrfmmm.2024.111856 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1345.xml |
| 035 | |a (DE-627)NLM370104463 | ||
| 035 | |a (NLM)38520879 | ||
| 035 | |a (PII)S0027-5107(24)00006-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Umar, Hassaan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Lung cancer is the one of the most prevalent cancer in the world. It kills more people from cancer than any other cause and is especially common in underdeveloped nations. With 1.2 million instances, it is also the most prevalent cancer in men worldwide, making about 16.7% of the total cancer burden. Surgery is the main form of curative treatment for early-stage lung cancer. However, the majority of patients had incurable advanced non-small cell lung cancer (NSCLC) recurrence after curative purpose surgery, which is indicative of the aggressiveness of the illness and the dismal outlook. The gold standard of treatment for NSCLC patients includes drug targeting of specific mutated genes drive in development of lung cancer. Furthermore, patients with advanced NSCLC and those with early-stage illness needing adjuvant therapy should use cisplatin as it is the more active platinum drug. So, this review encompasses the non-small cell lung cancer microenvironment, treatment approaches, and use of cisplatin as a first-line regimen for NSCLC, its mechanism of action, cisplatin resistance in NSCLC and also the prevention strategies to revert the drug resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cisplatin | |
| 650 | 4 | |a Drug resistance | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Mechanism | |
| 650 | 4 | |a Nanomedicine | |
| 650 | 4 | |a non-small cell lung cancer | |
| 700 | 1 | |a Wahab, Habibah A |e verfasserin |4 aut | |
| 700 | 1 | |a Attiq, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Amjad, Muhammad Wahab |e verfasserin |4 aut | |
| 700 | 1 | |a Bukhari, Syed Nasir Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Waqas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mutation research |d 1964 |g 828(2024) vom: 19. März, Seite 111856 |w (DE-627)NLM000034088 |x 1873-135X |7 nnns |
| 773 | 1 | 8 | |g volume:828 |g year:2024 |g day:19 |g month:03 |g pages:111856 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mrfmmm.2024.111856 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 828 |j 2024 |b 19 |c 03 |h 111856 | ||